FDA calendar · February 2023 · built from SEC filings

PDUFA dates February 2023: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in February 2023. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in February 2023

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

February 2023: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
February 1, 2023Tezspire (tezepelumab-ekko)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
February 1, 2023Jesduvroq (daprodustat)GSKFDA approval—ApprovedFDA Novel Drug Approvals
February 7, 2023VOQUEZNA® (vonoprazan)PHATComplete Response Letter—CRL issuedFDA Complete Response Letters
February 8, 2023Aduhelm (aducanumab-avwa)BIIBLabel expansion—ApprovedopenFDA Drugs@FDA
February 8, 2023PAVBLU® (aflibercept)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2023Jemperli (dostarlimab-gxly)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
February 9, 2023Cibinqo (abrocitinib)PFELabel expansion—ApprovedopenFDA Drugs@FDA
February 10, 2023Tecfidera (dimethyl fumarate)BIIBLabel expansion—ApprovedopenFDA Drugs@FDA
February 10, 2023Vumerity (diroximel fumarate)BIIBLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023Yervoy® (ipilimumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023Opdivo® (nivolumab)BMYLabel expansion—ApprovedopenFDA Drugs@FDA
February 15, 2023NARCANEBSAdvisory committee—PositiveSEC Form 10-K
February 15, 2023Benlysta (belimumab)GSKLabel expansion—ApprovedopenFDA Drugs@FDA
February 17, 2023AUSTEDO (deutetrabenazine)TEVAFDA approval—ApprovedSEC 8-K Exhibit 99.1
February 17, 2023FILSPARI (sparsentan)TVTXFDA approval—ApprovedFDA Novel Drug Approvals
February 27, 2023Daptomycin (daptomycin)BAXLabel expansion—ApprovedopenFDA Drugs@FDA
February 28, 2023SKYCLARYS® (omaveloxolone)BIIBFDA approvalTo treat Friedrich’s ataxiaApprovedFDA Novel Drug Approvals
February 28, 2023omecamtivCYTKComplete Response Letterchronic heart failure with HFrEFCRL issuedSEC Form 10-Q
February 28, 2023Kevzara (sarilumab)SNYLabel expansion—ApprovedopenFDA Drugs@FDA

February 2023: dated readouts

DateDrugCompanyEventIndicationStatusSource
Feb 2023Month disclosedRGX-111RGNXInterim readout—PositiveSEC 8-K Exhibit 99.1

February 2023: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Feb 2023Month disclosedbuntanetapANVSTrial start—CompletedSEC Form 10-K
Feb 2023Month disclosedselcodebart (DISC-0974)IRONTrial start—CompletedSEC Form 10-K
Feb 2023Month disclosedNC525NXTCTrial start—Completedsec_424b
Feb 2023Month disclosedefzofitimod (ATYR1923)ATYRTrial start—Completedsec_424b
Feb 2023Month disclosedKPI-012KALATrial start—CompletedSEC Form 10-K

Questions

What PDUFA dates are in February 2023?

0 PDUFA dates fell in February 2023. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.